Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

Drugging the Folate Pathway in Mycobacterium tuberculosis: The Role of Multi-targeting Agents.

Hajian B, Scocchera E, Shoen C, Krucinska J, Viswanathan K, G-Dayanandan N, Erlandsen H, Estrada A, Mikušová K, Korduláková J, Cynamon M, Wright D.

Cell Chem Biol. 2019 Jun 20;26(6):781-791.e6. doi: 10.1016/j.chembiol.2019.02.013. Epub 2019 Mar 28.

PMID:
30930162
2.

In Vitro Activities of Omadacycline against Rapidly Growing Mycobacteria.

Shoen C, Benaroch D, Sklaney M, Cynamon M.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02522-18. doi: 10.1128/AAC.02522-18. Print 2019 May.

PMID:
30858221
3.

Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research.

Daniel-Wayman S, Abate G, Barber DL, Bermudez LE, Coler RN, Cynamon MH, Daley CL, Davidson RM, Dick T, Floto RA, Henkle E, Holland SM, Jackson M, Lee RE, Nuermberger EL, Olivier KN, Ordway DJ, Prevots DR, Sacchettini JC, Salfinger M, Sassetti CM, Sizemore CF, Winthrop KL, Zelazny AM.

Am J Respir Crit Care Med. 2019 Apr 15;199(8):947-951. doi: 10.1164/rccm.201807-1273PP. No abstract available.

PMID:
30428263
4.

A call to arms: Unifying the fight against resistance.

Kaushansky A, Hedstrom L, Goldman A, Singh J, Yang PL, Rathod PK, Cynamon M, Wodarz D, Mahadevan D, Tomaras A, Navia MA, Schiffer CA.

Sci Signal. 2018 Oct 23;11(553). pii: eaav0442. doi: 10.1126/scisignal.aav0442.

PMID:
30352947
5.

Therapy for Mycobacterium kansasii Infection: Beyond 2018.

DeStefano MS, Shoen CM, Cynamon MH.

Front Microbiol. 2018 Sep 24;9:2271. doi: 10.3389/fmicb.2018.02271. eCollection 2018.

6.

Modeling the HIV-1 Antiretroviral Therapeutic Drug Interaction.

Cynamon MH, Damianopoulos EN.

AIDS Res Hum Retroviruses. 2018 Aug 3. doi: 10.1089/AID.2018.0113. [Epub ahead of print]

PMID:
30073843
7.

In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis.

Shoen C, DeStefano M, Hafkin B, Cynamon M.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00493-18. doi: 10.1128/AAC.00493-18. Print 2018 Aug.

8.

2-N-Arylthiazole inhibitors of Mycobacterium tuberculosis.

Clark MP, Wang T, Perola E, Deininger DD, Zuccola HJ, Jones SM, Gao H, VanderVen BC, Russell DG, Shoen CM, Cynamon MH, Thomson JA, Locher CP.

Bioorg Med Chem Lett. 2017 Sep 1;27(17):3987-3991. doi: 10.1016/j.bmcl.2017.07.067. Epub 2017 Jul 27.

PMID:
28778468
9.

Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment.

Anthony RM, Cynamon M, Hoffner S, Werngren J, den Hertog AL, van Soolingen D.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00258-17. doi: 10.1128/AAC.00258-17. Print 2017 Jun. No abstract available.

10.

In vitro activity of a novel compound, Mul-1867, against clinically significant fungi Candida spp. and Aspergillus spp.

Tetz G, Cynamon M, Hendricks G, Vikina D, Tetz V.

Int J Antimicrob Agents. 2017 Jul;50(1):47-54. doi: 10.1016/j.ijantimicag.2017.02.011. Epub 2017 Apr 27.

PMID:
28457835
11.

Propargyl-Linked Antifolates Are Potent Inhibitors of Drug-Sensitive and Drug-Resistant Mycobacterium tuberculosis.

Hajian B, Scocchera E, Keshipeddy S, G-Dayanandan N, Shoen C, Krucinska J, Reeve S, Cynamon M, Anderson AC, Wright DL.

PLoS One. 2016 Aug 31;11(8):e0161740. doi: 10.1371/journal.pone.0161740. eCollection 2016.

12.

Antiinfectives targeting enzymes and the proton motive force.

Feng X, Zhu W, Schurig-Briccio LA, Lindert S, Shoen C, Hitchings R, Li J, Wang Y, Baig N, Zhou T, Kim BK, Crick DC, Cynamon M, McCammon JA, Gennis RB, Oldfield E.

Proc Natl Acad Sci U S A. 2015 Dec 22;112(51):E7073-82. doi: 10.1073/pnas.1521988112. Epub 2015 Dec 7.

13.

Oxa, Thia, Heterocycle, and Carborane Analogues of SQ109: Bacterial and Protozoal Cell Growth Inhibitors.

Li K, Wang Y, Yang G, Byun S, Rao G, Shoen C, Yang H, Gulati A, Crick DC, Cynamon M, Huang G, Docampo R, No JH, Oldfield E.

ACS Infect Dis. 2015 May 8;1(5):215-221.

14.

Clinical isolates of Candida albicans, Candida tropicalis, and Candida krusei have different susceptibilities to Co(II) and Cu(II) complexes of 1,10-phenanthroline.

Hoffman AE, Miles L, Greenfield TJ, Shoen C, DeStefano M, Cynamon M, Doyle RP.

Biometals. 2015 Apr;28(2):415-23. doi: 10.1007/s10534-015-9825-0. Epub 2015 Feb 7.

PMID:
25663372
15.

The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents.

Grossman TH, Shoen CM, Jones SM, Jones PL, Cynamon MH, Locher CP.

Antimicrob Agents Chemother. 2015 Mar;59(3):1534-41. doi: 10.1128/AAC.04271-14. Epub 2014 Dec 22.

16.

A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections.

Locher CP, Jones SM, Hanzelka BL, Perola E, Shoen CM, Cynamon MH, Ngwane AH, Wiid IJ, van Helden PD, Betoudji F, Nuermberger EL, Thomson JA.

Antimicrob Agents Chemother. 2015 Mar;59(3):1455-65. doi: 10.1128/AAC.04347-14. Epub 2014 Dec 22.

17.

Metabolic and bactericidal effects of targeted suppression of NadD and NadE enzymes in mycobacteria.

Rodionova IA, Schuster BM, Guinn KM, Sorci L, Scott DA, Li X, Kheterpal I, Shoen C, Cynamon M, Locher C, Rubin EJ, Osterman AL.

MBio. 2014 Feb 18;5(1). pii: e00747-13. doi: 10.1128/mBio.00747-13.

18.

Co(II) and Cu(II) pyrophosphate complexes have selectivity and potency against Mycobacteria including Mycobacterium tuberculosis.

Hoffman AE, DeStefano M, Shoen C, Gopinath K, Warner DF, Cynamon M, Doyle RP.

Eur J Med Chem. 2013;70:589-93. doi: 10.1016/j.ejmech.2013.10.044. Epub 2013 Oct 23.

PMID:
24211634
19.

Inhibition of mycobacterial alanine racemase activity and growth by thiadiazolidinones.

Lee Y, Mootien S, Shoen C, Destefano M, Cirillo P, Asojo OA, Yeung KR, Ledizet M, Cynamon MH, Aristoff PA, Koski RA, Kaplan PA, Anthony KG.

Biochem Pharmacol. 2013 Jul 15;86(2):222-30. doi: 10.1016/j.bcp.2013.05.004. Epub 2013 May 13.

20.

A Modified Bacillus Calmette-Guérin (BCG) Vaccine with Reduced Activity of Antioxidants and Glutamine Synthetase Exhibits Enhanced Protection of Mice despite Diminished in Vivo Persistence.

Shoen CM, DeStefano MS, Hager CC, Tham KT, Braunstein M, Allen AD, Gates HO, Cynamon MH, Kernodle DS.

Vaccines (Basel). 2013 Jan 11;1(1):34-57. doi: 10.3390/vaccines1010034.

21.

In vitro activity of TP-271 against Mycobacterium abscessus, Mycobacterium fortuitum, and Nocardia species.

Cynamon M, Jureller J, Desai B, Ramachandran K, Sklaney M, Grossman TH.

Antimicrob Agents Chemother. 2012 Jul;56(7):3986-8. doi: 10.1128/AAC.00743-12. Epub 2012 May 14.

22.

Thiadiazolidinones: a new class of alanine racemase inhibitors with antimicrobial activity against methicillin-resistant Staphylococcus aureus.

Ciustea M, Mootien S, Rosato AE, Perez O, Cirillo P, Yeung KR, Ledizet M, Cynamon MH, Aristoff PA, Koski RA, Kaplan PA, Anthony KG.

Biochem Pharmacol. 2012 Feb 1;83(3):368-77. doi: 10.1016/j.bcp.2011.11.021. Epub 2011 Nov 29.

23.

Design, synthesis, and biological evaluation of novel fluorinated ethanolamines.

Fustero S, Cuñat AC, Flores S, Báez C, Oliver J, Cynamon M, Gütschow M, Mertens MD, Delgado O, Tresadern G, Trabanco AA.

Chemistry. 2011 Dec 23;17(52):14772-84. doi: 10.1002/chem.201102078. Epub 2011 Nov 24.

PMID:
22113787
24.

In vitro activity of JPC 2067 alone and in combination with sulfamethoxazole against nocardia species.

Mookherjee S, Shoen C, Cynamon M.

Antimicrob Agents Chemother. 2012 Feb;56(2):1133-4. doi: 10.1128/AAC.05855-11. Epub 2011 Nov 21.

25.

Effects of opsonization of Rhodococcus equi on bacterial viability and phagocyte activation.

Dawson DR, Nydam DV, Price CT, Graham JE, Cynamon MH, Divers TJ, Felippe MJ.

Am J Vet Res. 2011 Nov;72(11):1465-75. doi: 10.2460/ajvr.72.11.1465.

PMID:
22023124
26.

New classes of alanine racemase inhibitors identified by high-throughput screening show antimicrobial activity against Mycobacterium tuberculosis.

Anthony KG, Strych U, Yeung KR, Shoen CS, Perez O, Krause KL, Cynamon MH, Aristoff PA, Koski RA.

PLoS One. 2011;6(5):e20374. doi: 10.1371/journal.pone.0020374. Epub 2011 May 26.

27.

A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy.

Pethe K, Sequeira PC, Agarwalla S, Rhee K, Kuhen K, Phong WY, Patel V, Beer D, Walker JR, Duraiswamy J, Jiricek J, Keller TH, Chatterjee A, Tan MP, Ujjini M, Rao SP, Camacho L, Bifani P, Mak PA, Ma I, Barnes SW, Chen Z, Plouffe D, Thayalan P, Ng SH, Au M, Lee BH, Tan BH, Ravindran S, Nanjundappa M, Lin X, Goh A, Lakshminarayana SB, Shoen C, Cynamon M, Kreiswirth B, Dartois V, Peters EC, Glynne R, Brenner S, Dick T.

Nat Commun. 2010 Aug 24;1:57. doi: 10.1038/ncomms1060.

28.

Emerging drugs for the treatment of tuberculosis.

Yew WW, Cynamon M, Zhang Y.

Expert Opin Emerg Drugs. 2011 Mar;16(1):1-21. doi: 10.1517/14728214.2011.521497. Epub 2010 Sep 26. Review.

PMID:
20868293
29.

In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.

Pucci MJ, Ackerman M, Thanassi JA, Shoen CM, Cynamon MH.

Antimicrob Agents Chemother. 2010 Aug;54(8):3478-80. doi: 10.1128/AAC.00287-10. Epub 2010 Jun 1.

30.

Solution versus fluorous versus solid-phase synthesis of 2,5-disubstituted 1,3-azoles. Preliminary antibacterial activity studies.

Sanz-Cervera JF, Blasco R, Piera J, Cynamon M, Ibáñez I, Murguía M, Fustero S.

J Org Chem. 2009 Dec 4;74(23):8988-96. doi: 10.1021/jo9016265.

PMID:
19894729
31.

The antituberculosis drug pyrazinamide affects the course of cutaneous leishmaniasis in vivo and increases activation of macrophages and dendritic cells.

Mendez S, Traslavina R, Hinchman M, Huang L, Green P, Cynamon MH, Welch JT.

Antimicrob Agents Chemother. 2009 Dec;53(12):5114-21. doi: 10.1128/AAC.01146-09. Epub 2009 Sep 21.

32.

Prevalence and risk factors for drug resistance among hospitalized tuberculosis patients in Georgia.

Vashakidze L, Salakaia A, Shubladze N, Cynamon M, Barbakadze K, Kikvidze M, Papitashvili L, Nonikashvili M, Solomonia N, Bejanishvili N, Khurtsilava I.

Int J Tuberc Lung Dis. 2009 Sep;13(9):1148-53.

33.

Preparation and antitubercular activities in vitro and in vivo of novel Schiff bases of isoniazid.

Hearn MJ, Cynamon MH, Chen MF, Coppins R, Davis J, Joo-On Kang H, Noble A, Tu-Sekine B, Terrot MS, Trombino D, Thai M, Webster ER, Wilson R.

Eur J Med Chem. 2009 Oct;44(10):4169-78. doi: 10.1016/j.ejmech.2009.05.009. Epub 2009 May 21.

34.

Pseudomonas aeruginosa acute prostatitis and urosepsis after sexual relations in a hot tub.

Dulabon LM, LaSpina M, Riddell SW, Kiska DL, Cynamon M.

J Clin Microbiol. 2009 May;47(5):1607-8. doi: 10.1128/JCM.02376-08. Epub 2009 Mar 18.

35.

Peptide deformylase inhibitors of Mycobacterium tuberculosis: synthesis, structural investigations, and biological results.

Pichota A, Duraiswamy J, Yin Z, Keller TH, Alam J, Liung S, Lee G, Ding M, Wang G, Chan WL, Schreiber M, Ma I, Beer D, Ngew X, Mukherjee K, Nanjundappa M, Teo JW, Thayalan P, Yap A, Dick T, Meng W, Xu M, Koehn J, Pan SH, Clark K, Xie X, Shoen C, Cynamon M.

Bioorg Med Chem Lett. 2008 Dec 15;18(24):6568-72. doi: 10.1016/j.bmcl.2008.10.040. Epub 2008 Oct 14.

PMID:
19008098
36.

Inhibition of M. tuberculosis in vitro in monocytes and in mice by aminomethylene pyrazinamide analogs.

Chung WJ, Kornilov A, Brodsky BH, Higgins M, Sanchez T, Heifets LB, Cynamon MH, Welch J.

Tuberculosis (Edinb). 2008 Sep;88(5):410-9. doi: 10.1016/j.tube.2008.06.001.

PMID:
18674969
37.

Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis.

Kurabachew M, Lu SH, Krastel P, Schmitt EK, Suresh BL, Goh A, Knox JE, Ma NL, Jiricek J, Beer D, Cynamon M, Petersen F, Dartois V, Keller T, Dick T, Sambandamurthy VK.

J Antimicrob Chemother. 2008 Oct;62(4):713-9. doi: 10.1093/jac/dkn269. Epub 2008 Jun 27.

PMID:
18587134
38.

Glycine betaine uptake by the ProXVWZ ABC transporter contributes to the ability of Mycobacterium tuberculosis to initiate growth in human macrophages.

Price CT, Bukka A, Cynamon M, Graham JE.

J Bacteriol. 2008 Jun;190(11):3955-61. doi: 10.1128/JB.01476-07. Epub 2008 Apr 4.

39.

Gatifloxacin in combination with rifampicin in a murine tuberculosis model.

Cynamon M, Sklaney MR, Shoen C.

J Antimicrob Chemother. 2007 Aug;60(2):429-32. Epub 2007 Jun 8.

PMID:
17561504
40.

Peptide deformylase inhibitors as potent antimycobacterial agents.

Teo JW, Thayalan P, Beer D, Yap AS, Nanjundappa M, Ngew X, Duraiswamy J, Liung S, Dartois V, Schreiber M, Hasan S, Cynamon M, Ryder NS, Yang X, Weidmann B, Bracken K, Dick T, Mukherjee K.

Antimicrob Agents Chemother. 2006 Nov;50(11):3665-73. Epub 2006 Sep 11.

41.

Telephone coverage and health survey estimates: evaluating the need for concern about wireless substitution.

Blumberg SJ, Luke JV, Cynamon ML.

Am J Public Health. 2006 May;96(5):926-31. Epub 2006 Mar 29.

42.

In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus.

Murphy CK, Mullin S, Osburne MS, van Duzer J, Siedlecki J, Yu X, Kerstein K, Cynamon M, Rothstein DM.

Antimicrob Agents Chemother. 2006 Mar;50(3):827-34.

43.
44.

The National Survey of Children's Health: a new data resource.

van Dyck P, Kogan MD, Heppel D, Blumberg SJ, Cynamon ML, Newacheck PW.

Matern Child Health J. 2004 Sep;8(3):183-8.

PMID:
15499874
45.

The activity of grepafloxacin in two murine models of Mycobacterium avium infection.

Cynamon MH, Sklaney M, Yeo AE.

J Infect Chemother. 2004 Jun;10(3):185-8.

PMID:
15290460
46.

Recurrent Mycobacterium xenopi infection in a patient with rheumatoid arthritis receiving etanercept.

Yim K, Nazeer SH, Kiska D, Rose FB, Brown D, Cynamon MH.

Scand J Infect Dis. 2004;36(2):150-4.

PMID:
15061673
47.

Short-course treatment regimen to identify potential antituberculous agents in a murine model of tuberculosis.

Shoen CM, DeStefano MS, Sklaney MR, Monica BJ, Slee AM, Cynamon MH.

J Antimicrob Chemother. 2004 Apr;53(4):641-5. Epub 2004 Feb 18.

PMID:
14973154
48.

Design and synthesis of antituberculars: preparation and evaluation against Mycobacterium tuberculosis of an isoniazid Schiff base.

Hearn MJ, Cynamon MH.

J Antimicrob Chemother. 2004 Feb;53(2):185-91. Epub 2003 Dec 19.

PMID:
14688045
49.

BB-3497, a peptide deformylase inhibitor, is active against Mycobacterium tuberculosis.

Cynamon MH, Alvirez-Freites E, Yeo AE.

J Antimicrob Chemother. 2004 Feb;53(2):403-5. Epub 2003 Dec 19. No abstract available.

PMID:
14688038
50.

In vitro susceptibility of nocardia species to cethromycin, clarithromycin and amikacin.

Alvirez-Freites E, Yeo AE, DeStefano MS, Cynamon MH.

Eur J Clin Microbiol Infect Dis. 2004 Jan;23(1):69-70. Epub 2003 Dec 10. No abstract available.

PMID:
14666401

Supplemental Content

Loading ...
Support Center